Releases

Print
2013
2012
2011
2010
2009
Archives

Category:

All
ı
Corporate Releases
ı
Press Releases
ı
Releases in Danish
May 22, 2013
Corporate Releases

Vortioxetine, a new multimodal agent in development for the treatment of major depression, shows effects on cognitive function in several preclinical animal models

May 18, 2013
Corporate Releases

Vortioxetine clinical phase III data show significant improvement in symptoms of major depression

May 16, 2013
Corporate Releases

Lundbeck increases its share capital by 9,772 shares (0.005% of outstanding shares) as a result of employee warrant exercise

May 3, 2013
Press Releases

Tomorrows researchers are found on the Festival of Research

May 1, 2013
Corporate Releases

Lundbeck is well on track to deliver on guidance for 2013

Apr 22, 2013
Press Releases

Lundbeck introduces Selincro® as the first and only medicine for the reduction of alcohol consumption in alcohol dependent patients

Apr 8, 2013
Press Releases

Lundbeck presents new data on Selincro from three phase III studies that consistently show a significant reduction in alcohol consumption in alcohol dependent patients with high risk drinking level

Apr 8, 2013
Corporate Releases

Lundbeck announces positive results for Brintellix™ (vortioxetine) in adult patients with major depression and inadequate response to SSRI or SNRI therapy

Mar 26, 2013
Corporate Releases

Lundbeck and Otsuka further expand their alliance and enter into collaboration for the development and commercialization of Lu AE58054 in development for Alzheimer's disease

Mar 21, 2013
Corporate Releases

Lundbeck held its Annual General Meeting on 21 March 2013 at the company's registered office

Mar 20, 2013
Press Releases

NEW DATA SHOW AZILECT® (RASAGILINE TABLETS) PROVIDED CLINICAL BENEFIT IN PATIENTS WITH EARLY PARKINSON'S WHEN ADDED TO SUBOPTIMALLY CONTROLLED PATIENTS ON DOPAMINE AGONIST THERAPY

Mar 7, 2013
Press Releases

Otsuka advancing rapidly in central nervous system disorders — Otsuka and Lundbeck expanding their existing collaboration

Feb 28, 2013
Corporate Releases

FDA approves once-monthly Abilify Maintena (aripiprazole) for extended-release injectable suspension for the treatment of schizophrenia

Feb 28, 2013
Corporate Releases

Lundbeck receives European marketing authorization for Selincro as the first therapy approved for the reduction of alcohol consumption

Feb 22, 2013
Corporate Releases

Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

Feb 20, 2013
Corporate Releases

Notice of annual general meeting

Feb 20, 2013
Corporate Releases

Lundbeck elects new chairman

Feb 12, 2013
Press Releases

Increased treatment rates of alcohol dependence can save almost 12,000 lives

Feb 6, 2013
Corporate Releases

Full year report 2012 - Lundbeck delivers on guidance and sales of New Products increase more than 70%

Feb 6, 2013
Corporate Releases

Annual Report 2012 for H. Lundbeck A/S

Jan 14, 2013
Press Releases

Patient groups give Lundbeck top marks

Jan 11, 2013
Press Releases

Lundbeck appoints new vice president of global pricing and market access

You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.